Sign In
Buy CHRO
$1.35
+0 (+0%)
At Close: Sep 30, 2025
Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023
10:00am, Monday, 18'th Mar 2024
FREEHOLD, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatm
Chromocell to Present at Sidoti Virtual Investor Conference March 13-14
09:00am, Monday, 11'th Mar 2024
AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatme
Benuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare Solutions
08:00am, Tuesday, 27'th Feb 2024
AUSTIN. Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Benuvia Operations, LLC (“Benuvia”), a leader in pharmaceutical innovation, and Chromocell Therapeutics Corp. (“Chromocell”), (NYSE American: C
Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million
04:47pm, Wednesday, 21'st Feb 2024
FREEHOLD, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (NYSE American: CHRO) (“Chromocell”, “our”, “us” or the “Company”), a clinical-stage biotech compa
U.S. IPO Weekly Recap: Nano-Caps Debut In Quiet Week
07:45am, Saturday, 17'th Feb 2024
U.S. IPO Weekly Recap: Nano-Caps Debut In Quiet Week
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
08:00am, Friday, 16'th Feb 2024
FREEHOLD, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (NYSE American: CHRO) (“Chromocell” or the “Company”), a clinical-stage biotech company focused on develop
IPO Update: Chromocell Therapeutics Seeks $8.7 Million In Micro-IPO
05:31pm, Thursday, 19'th Oct 2023
Chromocell Therapeutics Corporation has filed for an $8.7 million IPO to develop its treatment for chronic pain conditions. The company's lead compound is being prepared for a Phase 2a study for eryth
